新的研究表明,肥胖成人体重下降的Mounjaro业绩优于Wegovy。 Mounjaro outperforms Wegovy for weight loss in obese adults, new study shows.

新英格兰医学杂志的一项新研究显示,Mounjaro比Wegovy在没有糖尿病的肥胖成人体重下降方面更有效。 A new study in the New England Journal of Medicine shows Mounjaro is more effective than Wegovy for weight loss in obese adults without diabetes. 72周后,Mounjaro使用者平均体重损失了20.2%,而Wegovy为13.7%。 After 72 weeks, Mounjaro users lost an average of 20.2% of their body weight, compared to 13.7% for Wegovy. Mounjaro的双重行为,模仿GLP-1和GIP荷尔蒙,可以解释其超高重量减量结果。 Mounjaro's dual action, mimicking both GLP-1 and GIP hormones, may explain its superior weight loss results. 这项研究由Mounjaro的制造者Eli Lilly赞助,有751人参加。 The study, sponsored by Eli Lilly, the maker of Mounjaro, involved 751 participants.